article thumbnail

Sarah Wicks Returns to HPM to Elevate Drug Development and Regulatory Practice

FDA Law Blog

Sarah brings a wealth of experience and a proven track record of advising innovative drug and biologics companies through the intricate landscape of product development and commercialization. Sarah’s a tremendous attorney who always understood HPM’s culture and commitment to client service. I am very excited to have Sarah rejoin HPM.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Leading API chemical companies in contract marketing

Pharmaceutical Technology

Various factors have contributed to the need and growth of API chemical suppliers such as rising healthcare expenditure, increasing disposable incomes, growing geriatric population, increasing incidence of chronic diseases, patent expiration of blockbuster drugs, increased consumption of generic drugs, and intervention of the new generation APIs.

Marketing 130
article thumbnail

CDER’s Office of Compliance Kicks Off Annual Report Season with Rundown of 2023’s Major Public Health Enforcement Initiatives

FDA Law Blog

OC had a major hand in drafting some key guidances this year, including the recent draft guidance on Post-Warning Letter Meetings Under GDUFA , a potentially important enforcement guide for generic drug makers that we blogged on back in September. This is important information for every drug maker and its quality teams.

article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages. Most of these generics are produced outside the US and recently there have been numerous recalls of generic drugs because of the failure of quality control.

article thumbnail

In the News: April 2021 Regulatory and Development Updates

Camargo

The public’s faith in drugs approved under the FDA’s accelerated approval program is not blind — it relies heavily on the industry’s follow-through on confirmatory trials and the FDA’s subsequent review and final approval. Drug Product. The meeting was prompted by a publication by Richard Pazdur, M.D., Indication. 7 Yes, 2 No.